Mulenga 1999.

Methods	Randomized controlled trial Length of follow up: 28 d Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: none Inclusion of all randomized participants in the final analysis: 160 analysed/163 randomized (98%)
Participants	Number randomized: 163 Age range: 14 to 54 years Gender: male and female (mainly male) Inclusion criteria: age 12 to 65 years; presence of acute uncomplicated falciparum malaria; parasitaemia between 1000 and 200,000/µL; weight 40 kg and above; no underlying disease Exclusion criteria: presence of mixed infections with other Plasmodium species; presence of concomitant disease (intercurrent febrile infections); inability to take oral treatment (persistent vomiting); pregnancy breastfeeding mother
Interventions	1. Atovaquone plus proguanil (1000 mg atovaquone and 400 mg proguanil daily over 3 d) 2. Sulfadoxine‐pyrimethamine (1500 mg sulfadoxine and 75 mg pyrimethamine as single dose)
Outcomes	1. 28‐d cure rate 2. Parasite clearance time 3. Fever clearance time
Notes	Location: Zambia Drug resistance: high for chloroquine